PMID- 24861494
OWN - NLM
STAT- MEDLINE
DCOM- 20150721
LR  - 20141113
IS  - 1743-1328 (Electronic)
IS  - 0161-6412 (Linking)
VI  - 37
IP  - 1
DP  - 2015 Jan
TI  - Preexisting dual antiplatelet treatment increases the risk of post-thrombolysis 
      intracranial hemorrhage in Chinese stroke patients.
PG  - 64-8
LID - 10.1179/1743132814Y.0000000390 [doi]
AB  - OBJECTIVE: Previous studies have shown conflicting results on the use of 
      antiplatelet (AP) agent and its risk of symptomatic intracerebral hemorrhage 
      (sICH) following thrombolysis for acute ischemic stroke. Our study was to explore 
      the safety of intravenous (IV) thrombolysis in Chinese stroke patients who were 
      on AP prior to stroke. METHODS: Data were collected from the thrombolysis 
      implementation and monitor of acute ischemic stroke in China (TIMS-China) 
      registry. Symptomatic ICH defined per SITS-MOST (safe implementation of 
      treatments in stroke-monitoring study), ECASS II (second European-Australasian 
      acute stroke study), and NINDS (National Institute of Neurological Disorders and 
      Stroke) criteria, 90-day functional outcome, and 7-day and 90-day mortalities 
      were compared between the stroke patients who were on mono and dual AP therapy. 
      RESULTS: A total of 157 (14.2%) patients received at least one AP drug within 24 
      hours before thrombolysis. Patients with preexisting dual AP treatment had higher 
      rate of sICH (14.3% (2/14) per SITS-MOST, 21.4% (3/14) per ECASS II definitions) 
      than those on no AP treatment. No significant difference was found in the rate of 
      sICH or 7-day or 90-day mortalities between the groups on aspirin (ASA) alone and 
      on no AP treatment. DISCUSSION: The risk of developing sICH is low when 
      thrombolysis is given to patients who are on ASA alone. However, there is 
      potential increased risk of sICH if a patient is on dual AP treatment.
FAU - Pan, Yuesong
AU  - Pan Y
FAU - Chen, Qidong
AU  - Chen Q
FAU - Liao, Xiaoling
AU  - Liao X
FAU - Zhao, Xingquan
AU  - Zhao X
FAU - Wang, Chunjuan
AU  - Wang C
FAU - Liu, Gaifen
AU  - Liu G
FAU - Liu, Liping
AU  - Liu L
FAU - Wang, Chunxue
AU  - Wang C
FAU - Wang, David
AU  - Wang D
FAU - Wang, Yilong
AU  - Wang Y
FAU - Wang, Yongjun
AU  - Wang Y
CN  - TIMS-China Investigators
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20140526
PL  - England
TA  - Neurol Res
JT  - Neurological research
JID - 7905298
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
SB  - IM
MH  - Aged
MH  - Brain Ischemia/*drug therapy/*epidemiology
MH  - China/epidemiology
MH  - Female
MH  - Fibrinolytic Agents/*adverse effects/therapeutic use
MH  - Humans
MH  - Injections, Intravenous
MH  - Intracranial Hemorrhages/chemically induced/*epidemiology
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*adverse effects/therapeutic use
MH  - Prospective Studies
MH  - Registries
MH  - Risk Factors
MH  - Thrombolytic Therapy/*adverse effects
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Antiplatelet,
OT  - Ischemic stroke,
OT  - Safety,
OT  - Symptomatic intracerebral hemorrhage,
OT  - Thrombolysis
EDAT- 2014/05/28 06:00
MHDA- 2015/07/22 06:00
CRDT- 2014/05/28 06:00
PHST- 2014/05/28 06:00 [entrez]
PHST- 2014/05/28 06:00 [pubmed]
PHST- 2015/07/22 06:00 [medline]
AID - 10.1179/1743132814Y.0000000390 [doi]
PST - ppublish
SO  - Neurol Res. 2015 Jan;37(1):64-8. doi: 10.1179/1743132814Y.0000000390. Epub 2014 
      May 26.